All News
RheumNow Podcast – Jack of All Subspecialties (10.1.2021)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com
Read Article
Cardiovascular Prevention Lacking in Rheumatoid Arthritis
An increased cardiovascular disease (CVD) risk in rheumatoid arthritis is well known and feared but an RA cohort study suggests that preventive medication use in RA patients lags behind that seen in diabetes mellitus (DM).
Read Article
RheumNow Podcast – Pounds of Prevention (3.5.2021)
Dr. Jack Cush reviews and discusses nearly a dozen news reports and journal articles from the past week on RheumNow.com.
Read Article
Post hoc study of Hidradenitis suppurativa (HS) phase 3 study w/ 588 pts rx w/ either PBO or adalimumab. 79% had elevated CRP. High CRP assoc w/ more severe HS, higher BMI (34 vs 28; P < .001), & lower odds of ADA response (OR 0.53). Activity or Obesity? https://t.co/ZQzumtW2LV https://t.co/FWaQMyP2TT
Dr. John Cush RheumNow ( View Tweet)
Benefit of Achieving Target Serum Urate Levels in Gout with Chronic Kidney Disease
A cohort study of gout patients with CKD stage 3 found that lowering serum urate (SUA) level to less than 6 mg/dL, lowered the risk for severe or end-stage kidney disease progression.… https://t.co/NsGUGvb5L5 https://t.co/QPBWA4VqTo
Dr. John Cush RheumNow ( View Tweet)
Data from Psoriasis Atherosclerosis and Cardiometabolic Disease Initiative & Stockholm Psoriasis Cohort (n=769 Pso Pts) finds that PsO severity (PASI) PASI assoc w/ GlycA levels (syst inflammation) & GlycA levels assoc w/ CVD risk (OR=1.23) https://t.co/IwUHILMpnI https://t.co/DnEF3yuTvg
Dr. John Cush RheumNow ( View Tweet)
Best of 2024: Mixed Long-term Effects of Calcium and Vitamin D in Postmenopausal Women
https://t.co/RxI1zlZ9YR https://t.co/vhsLi6HQAS
Dr. John Cush RheumNow ( View Tweet)
FDA has approved Eli Lilly’s GLP-1 drug Zepbound [tirzepatide] to treat moderate to severe obstructive sleep apnea in adults with obesity in combination with increased physical activity and a reduced-calorie diet.” https://t.co/rYiM6JzmDX https://t.co/hO6CgH9pVs
Dr. John Cush RheumNow ( View Tweet)
GLP-1 Agonists Show Promise in Slowing Kidney Disease in Lupus Nephritis
Glucagon-like peptide-1 receptor agonists (GLP-1Ra) have transformed the treatment landscape for type 2 diabetes and obesity. #ACR24
https://t.co/6QqEH8X2VJ https://t.co/Ch2i9zZYii
Dr. John Cush RheumNow ( View Tweet)
Mitochondria: the powerhouse of the cell—but the fuel behind gout flares?
#ACR24 @RheumNow https://t.co/lV4dovLV18
Akhil Sood MD AkhilSoodMD ( View Tweet)
Pts w #osteoarthritis and T2 DM
👇
Who Have
⬆️pain
Have
worse control of #diabetes
Even after adjusting for #BMI
Chicken or egg - which comes 1st
🤷♀️
#ACR24 @RheumNow @ACRheum
Abst#2110 https://t.co/eN2xAw0EMG
Janet Pope Janetbirdope ( View Tweet)
Updated ACR guidelines on management of lupus nephritis (LN). Consider early biopsy. Focus on triple therapy in LN. From the panel discussion, Tacrolimus can be an alternative to CNI (Voclosporin) where there is no access to this. Manage comorbidities such as CV risk, bone… https://t.co/4R02YnRXDP https://t.co/3J7YcF5ucQ
Links:
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Does adding a Clofutriben (HSD-1 inhibitor) w/ prednisone minimize the risks of steroid toxicities in #PMR patients?
VS placebo, PMR patients who received Clofutriben + Prednisone had substantial reductions in bone, lipid, and glycemic control parameters
@RheumNow #ACR24
Akhil Sood MD AkhilSoodMD ( View Tweet)
I have no doubt many of our RA patients will take GLP-1 agonists in the future.
Here's some data @UCLA showing significant differences in not just body weight and HbA1c, but pain.
Will be fascinating to see what it does for grumbling disease activity!
#ACR24 ABST2259 @RheumNow https://t.co/HdOPACEo3A
David Liew drdavidliew ( View Tweet)
Effective RA therapy is about more than just joints
🇪🇸 RA cohort
TNFi for first 24w led to:
Lean mass index i.e. muscle going up
Fat mass index i.e. fat trending down
Muscle & fat composition are important
Systemic Rx can deliver systemic benefits
#ACR24 ABST1348 @RheumNow https://t.co/mZjcHwxMgW
David Liew drdavidliew ( View Tweet)
Low uptake of SGLT2i in Lupus nephritis
SGLT2i users had similar adverse event rates as ACEi/ARB users
SGLT2i users experienced more weight loss
#ACR24 @rheumnow abst#1534 https://t.co/tB5o7tyhu5
Bella Mehta bella_mehta ( View Tweet)
An Artificial Intelligence-Based Gout Management System Reduced Chronic Kidney Disease Incident and Improves achieving Target Serum Urate levels. AI lowered incid. of CKD stage≥ 3 by 47%, & incr # achieving target SUA <6mg/dl with(59% vs 26%, p<0.001). https://t.co/INULBvaKF9 https://t.co/fkPgbscOXj
Dr. John Cush RheumNow ( View Tweet)
NHANES study of 11264 adolescents (12–17 yrs) found Hyperuricemia (≥ 5.5 mg/dL) in 33%, (51% males, 13% females) and was more prevalent with obesity and in non-Hispanic Asians https://t.co/rwUt1Cgg9b https://t.co/dFr1LeX0nC
Dr. John Cush RheumNow ( View Tweet)
A study of 7459 adults with diabetes, shows that regular bicycling is associated with a 22-32% reduction in all cause mortality and CVD mortality - with a loss of benefit to those who stop. https://t.co/wjEJXAu0zx
Links:
Dr. John Cush RheumNow ( View Tweet)
UTSW Rheum Grand Rounds - IgG4 Dz renal involvement; most common is tubulointerstitial nephritis
@UTSWIMchief https://t.co/q8dZbgmvfK
Dr. John Cush RheumNow ( View Tweet)
